1. Home
  2. WINA vs DVAX Comparison

WINA vs DVAX Comparison

Compare WINA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Winmark Corporation

WINA

Winmark Corporation

HOLD

Current Price

$421.30

Market Cap

1.5B

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.97

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WINA
DVAX
Founded
1988
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
1993
2004

Fundamental Metrics

Financial Performance
Metric
WINA
DVAX
Price
$421.30
$10.97
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$26.50
AVG Volume (30 Days)
85.0K
1.7M
Earning Date
10-15-2025
11-05-2025
Dividend Yield
2.71%
N/A
EPS Growth
2.56
N/A
EPS
11.21
N/A
Revenue
$84,517,400.00
$330,514,000.00
Revenue This Year
$7.05
$24.63
Revenue Next Year
$3.60
$15.85
P/E Ratio
$37.40
N/A
Revenue Growth
3.35
26.73
52 Week Low
$295.79
$9.20
52 Week High
$527.37
$14.63

Technical Indicators

Market Signals
Indicator
WINA
DVAX
Relative Strength Index (RSI) 49.91 51.72
Support Level $405.86 $10.79
Resistance Level $437.10 $11.10
Average True Range (ATR) 15.54 0.31
MACD 2.62 -0.07
Stochastic Oscillator 62.43 35.79

Price Performance

Historical Comparison
WINA
DVAX

About WINA Winmark Corporation

Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: